In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Bruce the dog reviews cultivated meat
In Scotland, Philip Lymbery, a journalist writing for The Scotsman has turned to his beloved pup Bruce to review Chick Bites dog treats, the...
Breaking nugget news: Japanese scientists create lab-growth chicken with circulatory system
In Tokyo, researchers have created the world’s largest, and most advanced, lab-growth chicken nugget.
Featuring “veins” that deliver nutrients and oxygen, the new nugget...
Be green on the green with biodegradable golf balls
In Vancouver, a company is selling golf balls that biodegrade in two weeks and are made from compressed corn starch, calcium carbonate, glycerin, and...